公开(公告)号：US12110297B2

公开(公告)日：2024-10-08

申请号：US18329986

申请日：2023-06-06

Applicant: AbbVie Inc.

Inventor： Jayanthy Jayanth ,  Mohamed-Eslam F. Mohamed ,  Ahmed A. Othman ,  Patrick J. Marroum ,  Peter T. Mayer ,  Ben Klünder

IPC: C07D487/14 ,  A61K9/00 ,  A61K31/4985 ,  A61K47/02 ,  A61K47/12 ,  A61K47/38 ,  C07D487/04

CPC classification number: C07D487/14 ,  A61K9/0053 ,  A61K31/4985 ,  A61K47/02 ,  A61K47/12 ,  A61K47/38 ,  C07D487/04 ,  C07B2200/13

Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.

公开(公告)号：US12077545B2

公开(公告)日：2024-09-03

申请号：US18530077

申请日：2023-12-05

Applicant: AbbVie Inc.

Inventor： Jayanthy Jayanth ,  Mohamed-Eslam F. Mohamed ,  Ahmed A. Othman ,  Patrick J. Marroum ,  Peter T. Mayer ,  Ben Klünder

IPC: A61K31/4985 ,  A61K9/00 ,  A61K47/02 ,  A61K47/12 ,  A61K47/38 ,  C07D487/04 ,  C07D487/14

CPC classification number: C07D487/14 ,  A61K9/0053 ,  A61K31/4985 ,  A61K47/02 ,  A61K47/12 ,  A61K47/38 ,  C07D487/04 ,  C07B2200/13

Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.

公开(公告)号：US20230312595A1

公开(公告)日：2023-10-05

申请号：US18328350

申请日：2023-06-02

Applicant: AbbVie Inc.

Inventor： Ayman Allian ,  Jayanthy Jayanth ,  Mohamed-Eslam F. Mohamed ,  Mathew M. Mulhern ,  Fredrik Lars Nordstrom ,  Ahmed A. Othman ,  Michael J. Rozema ,  Lakshmi Bhagavatula ,  Patrick J. Marroum ,  Peter T. Mayer ,  Ahmad Y. Sheikh ,  Thomas B. Borchardt ,  Ben Klünder

IPC: C07D487/14 ,  A61K47/12 ,  A61K47/38 ,  A61K9/00 ,  A61K31/4985

CPC classification number: C07D487/14 ,  A61K47/12 ,  A61K47/38 ,  A61K9/0053 ,  A61K31/4985 ,  C07B2200/13

Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.

公开(公告)号：US20230058001A1

公开(公告)日：2023-02-23

申请号：US17951334

申请日：2022-09-23

Applicant: AbbVie Inc.

Inventor： Ayman Allian ,  Jayanthy Jayanth ,  Mohamed-Eslam F. Mohamed ,  Mathew M. Mulhern ,  Fredrik Lars Nordstrom ,  Ahmed A. Othman ,  Michael J. Rozema ,  Lakshmi Bhagavatula ,  Patrick J. Marroum ,  Peter T. Mayer ,  Ahmad Y. Sheikh ,  Thomas B. Borchardt ,  Ben Klünder

IPC: C07D487/14 ,  A61K9/00 ,  A61K31/4985 ,  A61K47/12 ,  A61K47/38

Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.

公开(公告)号：US20230057084A1

公开(公告)日：2023-02-23

申请号：US17951332

申请日：2022-09-23

Applicant: AbbVie Inc.

Inventor： Ayman Allian ,  Jayanthy Jayanth ,  Mohamed-Eslam F. Mohamed ,  Mathew M. Mulhern ,  Fredrik Lars Nordstrom ,  Ahmed A. Othman ,  Michael J. Rozema ,  Lakshmi Bhagavatula ,  Patrick J. Marroum ,  Peter T. Mayer ,  Ahmad Y. Sheikh ,  Thomas B. Borchardt ,  Ben Klünder

IPC: C07D487/14 ,  A61K9/00 ,  A61K31/4985 ,  A61K47/12 ,  A61K47/38

Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.

公开(公告)号：US20220281882A1

公开(公告)日：2022-09-08

申请号：US17668249

申请日：2022-02-09

Applicant: AbbVie Inc.

Inventor： Ayman Allian ,  Jayanthy Jayanth ,  Mohamed-Eslam F. Mohamed ,  Mathew Mulhern ,  Fredrik Lars Nordstrom ,  Ahmed A. Othman ,  Michael J. Rozema ,  Lakshmi Bhagavatula ,  Patrick J. Marroum ,  Peter T. Mayer ,  Ahmad Y. Sheikh ,  Thomas B. Borchardt ,  Ben Klünder ,  Aileen L. Pangan ,  Jaclyn Kay Anderson ,  In-Ho Song ,  Jose Jeffrey V. Enejosa

IPC: C07D487/14 ,  A61K9/00 ,  A61K31/4985 ,  A61K47/12 ,  A61K47/38

Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-α]pyrrolo[2.3-]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis), kits, methods of synthesis, and products-by-process.

公开(公告)号：US20220267342A1

公开(公告)日：2022-08-25

申请号：US17735061

申请日：2022-05-02

Applicant: AbbVie Inc.

Inventor： Ayman Allian ,  Jayanthy Jayanth ,  Mohamed-Eslam F. Mohamed ,  Mathew Mulhern ,  Fredrik Lars Nordstrom ,  Ahmed A. Othman ,  Michael J. Rozema ,  Lakshmi Bhagavatula ,  Patrick J. Marroum ,  Peter T. Mayer ,  Ahmad Y. Sheikh ,  Thomas B. Borchardt ,  Ben Klünder

IPC: C07D487/14 ,  A61K47/12 ,  A61K31/4985 ,  A61K9/00 ,  A61K47/38

Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis and various spondyloarthritic conditions, including types of axial spondyloarthritis (axSpA)), kits, methods of synthesis, and products-by-process. In various aspects, provided are methods for treating active non-radiographic axSpA (nr-axSpA) and methods for treating active ankylosing spondylitis (AS).

公开(公告)号：US10981924B2

公开(公告)日：2021-04-20

申请号：US16983701

申请日：2020-08-03

Applicant: AbbVie Inc.

Inventor： Jayanthy Jayanth ,  Ben Klünder ,  Mohamed-Eslam Mohamed ,  Ahmed A. Othman ,  Patrick J. Marroum ,  Peter T. Mayer

IPC: C07D487/14 ,  A61K9/00 ,  A61K47/12 ,  A61K47/38 ,  A61K31/4985

Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.

公开(公告)号：US10202393B2

公开(公告)日：2019-02-12

申请号：US15945225

申请日：2018-04-04

Applicant: AbbVie Inc.

Inventor： Jayanthy Jayanth ,  Patrick J. Marroum ,  Peter T. Mayer ,  Mohamed-Eslam F. Mohamed ,  Ahmed A. Othman ,  Ben Klünder

IPC: A01N43/58 ,  A01N43/60 ,  A61K31/50 ,  A61K31/495 ,  C07D487/14 ,  A61K9/00 ,  A61K31/4985 ,  A61K47/12 ,  A61K47/38

Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.

公开(公告)号：US20180222914A1

公开(公告)日：2018-08-09

申请号：US15945231

申请日：2018-04-04

Applicant: AbbVie Inc.

Inventor： Jayanthy Jayanth ,  Patrick J. Marroum ,  Peter T. Mayer ,  Mohamed-Eslam F. Mohamed ,  Ahmed A. Othman

IPC: C07D487/14 ,  A61K47/38 ,  A61K31/4985 ,  A61K9/00 ,  A61K47/12

CPC classification number: C07D487/14 ,  A61K9/0053 ,  A61K31/4985 ,  A61K47/12 ,  A61K47/38 ,  C07B2200/13

Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.